The following is a response from the Southern Cross Health Society to a Q&A article with Ophthalmology New Zealand (ONZ) about its work with the country’s health insurance providers and Southern Cross’ delay in funding products, such as Xen for glaucoma patients.
Premium subscriber content
Sign in if you have a Digital or Print + Digital subscription. Don’t have one yet? Digital subscribers get full access to this article from $40/year +GST.
- Premium exclusive content
- Full digital magazine archive
- Early access to new articles
